Physician profile
Theodore S Thomas
NPI 1669477113
$1,099.46
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $826 · 2020: $273.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $202.28 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $165.28 | 2019-2020 | |
| Amgen INC. | $146.81 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $115.46 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $83.97 | 2019 | |
| Abbott Laboratories | $62.38 | 2019 | |
| Vifor Pharma, INC. | $41.86 | 2019 | |
| Shire North American Group INC | $39.28 | 2019 | |
| Akebia Therapeutics INC | $34.85 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $31.19 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $24.54 | 2019 | |
| Novo Nordisk INC | $22.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.06 | 2019 | |
| Daiichi Sankyo INC. | $19.54 | 2019 | |
| Fresenius USA Marketing, INC. | $19.27 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.24 | 2019 | |
| Glaxosmithkline, LLC. | $17.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.05 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.